Core Insights - Scorpius Holdings, Inc. has announced a collaboration with KaloCyte to enhance manufacturing efficiencies for KaloCyte's lead candidate, ErythroMer™, an artificial red blood cell designed to address critical blood loss situations [1][2] - The partnership aims to establish a commercial-scale manufacturing agreement, emphasizing Scorpius' commitment to making life-saving therapies widely available [1][2] Company Overview - Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) that provides a comprehensive suite of services including analytical testing, process development, and cGMP clinical manufacturing [4] - The company operates state-of-the-art facilities in San Antonio, TX, and focuses on rapidly advancing biologic programs to the clinic and beyond [4] KaloCyte Overview - KaloCyte is a pre-clinical biotech startup developing ErythroMer™, a bioengineered artificial red blood cell substitute aimed at treating traumatic hemorrhage when stored blood is unavailable [3] - The product is designed to be a universal option for all blood types and has the potential to serve a $7 billion U.S. market [3] - KaloCyte has received $17 million in grants from DARPA and NIH, along with over $5 million in investor funding, and is seeking Series A financing for IND-enabling studies and Phase 1 clinical trials [3]
Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™